Welcome to our dedicated page for Nautilus Biotechnology SEC filings (Ticker: NAUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nautilus Biotechnology filings document SEC reporting for a Nasdaq-listed life sciences tools company developing single-molecule proteome analysis technology. Recent Form 8-K reports furnish quarterly and annual financial results and record material events, including continued-listing compliance with Nasdaq rules.
Proxy materials cover annual meeting procedures, director elections, stockholder voting matters, and board governance. The filings also identify the company's registered common stock under ticker NAUT and provide formal records of its capital structure, governance actions, and public-company reporting obligations.
Mallick Parag reported acquisition or exercise transactions in this Form 4 filing.
Nautilus Biotechnology, Inc. reported that Chief Scientist and 10% owner Parag Mallick was granted stock options covering 280,000 shares of common stock. These options were awarded on March 2, 2026 and are structured as a long-term equity incentive.
The grant vests over time, subject to Mallick’s continued service to the company. Twenty-five percent of the options vest on the one-year anniversary of the January 1, 2026 vesting commencement date, with the remaining options vesting in equal monthly installments over the following thirty-six months.
Nautilus Biotechnology CEO Sujal M. Patel received a grant of 650,000 stock options described as a right to buy shares at an exercise price of $0.0000 per share. According to the vesting terms, 25% of the options vest on the one-year anniversary of the vesting commencement date of January 1, 2026, with the remaining shares vesting in equal monthly installments over the following 36 months, contingent on his continued service.
Nautilus Biotechnology reported that Senior VP of Product Development Sankar Subramanian received a grant of stock options covering 160,000 shares on March 2, 2026. The options have an exercise price of $0.00 per share and represent a new award rather than an open-market purchase.
According to the vesting terms, 25% of the option shares vest on the one-year anniversary of the January 1, 2026 vesting commencement date, with the remaining shares vesting in equal monthly installments over the following 36 months, contingent on continued service as a “Service Provider.”
Nautilus Biotechnology reported that Chief People Officer Gwen E. Weld received a grant of stock options covering 160,000 shares of common stock. The award is classified as a grant or other acquisition and was reported as a derivative security with no purchase price listed per share.
The options vest over time, starting with 25% of the shares vesting on the one-year anniversary of the January 1, 2026 vesting commencement date. The remaining shares vest in equal monthly installments over the following 36 months, contingent on Weld’s continued service to the company.
Nautilus Biotechnology granted General Counsel Matthew B. Murphy a stock option covering 160,000 shares of common stock. The option was awarded at an exercise price of $0.00 per share, so he did not pay anything at grant. Vesting is tied to his continued service: 25% of the option vests on the one-year anniversary of the January 1, 2026 vesting commencement date, with the remaining shares vesting in equal monthly installments over the following 36 months. This award increases his directly held option position to 160,000 shares.
Nautilus Biotechnology Chief Marketing Officer awarded stock options
Nautilus Biotechnology granted Chief Marketing Officer Kentaro Suzuki a stock option to acquire 160,000 shares on March 2, 2026. The option has a $0.00 exercise price and vests over time, starting from a vesting commencement date of January 1, 2026.
One quarter of the option vests on the one-year anniversary of the vesting commencement date, with the remaining shares vesting monthly in equal installments, subject to his continued service with the company.
Nautilus Biotechnology files its annual report describing a development-stage proteomics platform built around its Nautilus Voyager instrument and Iterative Mapping method. The company aims to measure single protein molecules at scale, targeting both broad proteome coverage and detailed proteoform analysis with high reproducibility.
Nautilus highlights a projected $57 billion proteomics market by 2030 with a 13% CAGR, and notes that about 95% of FDA-approved drug targets are proteins. It is pursuing a phased commercialization strategy, including research collaborations and an Iterative Mapping Early Access Program launched in January 2026 for Tau proteoform analysis.
Nautilus Biotechnology reported lower operating expenses and a narrower net loss for the fourth quarter and full year 2025 as it advances its single‑molecule proteomics platform toward an expected commercial launch in late 2026. Operating expenses were $15.4 million in Q4 2025, down from $20.0 million a year earlier, and $66.8 million for 2025 versus $81.5 million in 2024, reflecting reduced salaries, stock-based compensation, development costs, and in‑process R&D.
Net loss improved to $13.8 million in Q4 2025 from $17.6 million in the prior-year quarter, and to $59.0 million for 2025 from $70.8 million in 2024. Cash, cash equivalents, and investments totaled $156.1 million as of December 31, 2025, and the company believes this will fund operations through 2027.
Nautilus highlighted progress in Tau proteoform work, a new broadscale assay format, a January 2026 Iterative Mapping Early Access Program, a Michael J. Fox Foundation-supported alpha‑synuclein collaboration, and unveiling of the Nautilus Voyager™ platform, while noting it does not anticipate material 2026 revenue and expects operating expenses to rise about 15–20% year over year.
Nautilus Biotechnology (NAUT) reported an insider share purchase on a Form 4. The company’s Chief Marketing Officer bought 4,000 shares of common stock on 11/06/2025 at $1.49 per share. Following the transaction, the officer beneficially owned 4,000 shares, held directly.
Nautilus Biotechnology (NAUT) regained Nasdaq listing compliance. The company received notice on November 3, 2025 that it meets Nasdaq Listing Rule 5550(a)(2) after its common stock closed at or above $1.00 per share for a minimum of ten consecutive business days. Nasdaq stated the matter is now closed.
Earlier in 2025, NAUT had fallen below the minimum bid-price requirement and was granted compliance periods through October 28, 2025, then transferred to The Nasdaq Capital Market on October 29, 2025 with additional time to cure. Regaining compliance supports the company’s continued listing on The Nasdaq Capital Market under the NAUT ticker.